全文获取类型
收费全文 | 210篇 |
免费 | 17篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 27篇 |
妇产科学 | 3篇 |
基础医学 | 19篇 |
口腔科学 | 5篇 |
临床医学 | 21篇 |
内科学 | 71篇 |
皮肤病学 | 1篇 |
神经病学 | 7篇 |
特种医学 | 42篇 |
外科学 | 7篇 |
综合类 | 3篇 |
预防医学 | 5篇 |
眼科学 | 1篇 |
药学 | 4篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 1篇 |
2018年 | 3篇 |
2016年 | 6篇 |
2015年 | 3篇 |
2014年 | 7篇 |
2013年 | 4篇 |
2012年 | 11篇 |
2011年 | 5篇 |
2010年 | 9篇 |
2009年 | 7篇 |
2008年 | 3篇 |
2007年 | 11篇 |
2006年 | 4篇 |
2005年 | 7篇 |
2004年 | 11篇 |
2003年 | 9篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 2篇 |
1999年 | 2篇 |
1998年 | 9篇 |
1997年 | 9篇 |
1996年 | 12篇 |
1995年 | 13篇 |
1994年 | 8篇 |
1993年 | 9篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 7篇 |
1988年 | 7篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 6篇 |
1977年 | 4篇 |
1976年 | 1篇 |
1975年 | 4篇 |
1942年 | 1篇 |
排序方式: 共有228条查询结果,搜索用时 15 毫秒
41.
Results of randomized controlled trials of low-versus high-osmolality contrast media 总被引:1,自引:0,他引:1
The authors reviewed 100 randomized controlled trials (RCTs) conducted in humans to compare safety or efficacy of new low-osmolality contrast media (LOM) with that of high-osmolality contrast media (HOM). Findings of the 43 RCTs judged to be of the highest quality suggest that the efficacy of LOM in imaging is equal or superior to that of HOM for all routes of administration. Heat sensation occurred less often with LOM for all routes and pain occurred less often with LOM for intraarterial routes. No differences were seen in nephrotoxicity or in frequency of nausea, vomiting, urticaria, bronchospasm, laboratory test abnormalities, or neurologic events. Greater cardiovascular changes were seen with HOM, including increased or decreased heart rate, increased left ventricular end-diastolic pressure, decreased systolic pressure, and QT prolongation, depending on route of administration. To demonstrate whether a reduction in clinically significant adverse outcomes truly occurs with LOM, trials will need to enlist larger numbers of patients and employ appropriate outcome measures. Future trials should stratify patients according to their risk of adverse reactions to provide better information about benefits of LOM in low- versus high-risk patients. 相似文献
42.
A survey was undertaken to examine the impact of Medicare's Prospective Payment System (PPS) and other recent changes in the health care environment on providers' decisions regarding acquisition of high-cost technologic equipment. The survey group included 199 hospitals and freestanding imaging centers known to have acquired magnetic resonance (MR) imaging units, as well as a random sample of 400 hospitals whose acquisition decisions were unknown to the authors. Fifty-eight percent of the known adopters and 61% of the randomly selected hospitals responded to the survey. Nonadopters' decisions were dominated by economic considerations, including the high cost of MR imagers and concerns about Medicare's reimbursement policies. Competition and a desire to provide the highest quality of care are counterbalancing the retardant effects of PPS, however, and are stimulating widespread diffusion of MR imagers. 相似文献
43.
Antonio C Lerario Antonio R Chacra Augusto Pimazoni-Netto Domingos Malerbi Jorge L Gross José EP Oliveira Marilia B Gomes Raul D Santos Reine MC Fonseca Roberto Betti Roberto Raduan 《Diabetology & metabolic syndrome》2010,2(1):35
The Brazilian Diabetes Society is starting an innovative project of quantitative assessment of medical arguments of and implementing a new way of elaborating SBD Position Statements. The final aim of this particular project is to propose a new Brazilian algorithm for the treatment of type 2 diabetes, based on the opinions of endocrinologists surveyed from a poll conducted on the Brazilian Diabetes Society website regarding the latest algorithm proposed by American Diabetes Association /European Association for the Study of Diabetes, published in January 2009.An additional source used, as a basis for the new algorithm, was to assess the acceptability of controversial arguments published in international literature, through a panel of renowned Brazilian specialists. Thirty controversial arguments in diabetes have been selected with their respective references, where each argument was assessed and scored according to its acceptability level and personal conviction of each member of the evaluation panel.This methodology was adapted using a similar approach to the one adopted in the recent position statement by the American College of Cardiology on coronary revascularization, of which not only cardiologists took part, but also specialists of other related areas. 相似文献
44.
45.
46.
S J Isakoff D Wang M Campone A Calles E Leip K Turnbull N Bardy-Bouxin L Duvillié E Calvo 《British journal of cancer》2014,111(11):2058-2066
Background:
This phase 1 study evaluated the maximum tolerated dose (MTD), safety, and efficacy of bosutinib (competitive Src/Abl tyrosine kinase inhibitor) plus capecitabine.Methods:
Patients with locally advanced/metastatic breast, pancreatic, or colorectal cancers; cholangiocarcinoma; or glioblastoma received bosutinib plus capecitabine at eight of nine possible dose combinations using an ‘up-down'' design to determine the toxicity contour of the combination.Results:
Among 32 enrolled patients, none of the 9 patients receiving MTD (bosutinib 300 mg once daily plus capecitabine 1000 mg m−2 twice daily) experienced dose-limiting toxicities (DLTs). Overall, 2 out of 31 (6%) evaluable patients experienced DLTs (grade 3 neurologic pain (n=1); grade 3 pruritus/rash and increased alanine aminotransferase (n=1)). Most common treatment-related adverse events (AEs) were diarrhoea, nausea, vomiting, palmar-plantar erythrodysesthesia (PPE), fatigue; most frequent grade 3/4 AEs: PPE, fatigue, and increased alanine/aspartate aminotransferase. Although diarrhoea was common, 91% of affected patients experienced maximum grade 1/2 events that resolved. Best overall confirmed partial response or stable disease >24 weeks (all tumour types) was observed in 6 and 13% of patients.Conclusions:
In this population of patients with advanced solid tumours, bosutinib plus capecitabine demonstrated a safety profile similar to that previously reported for bosutinib or capecitabine monotherapy; limited efficacy was observed. 相似文献47.
48.
49.
50.